HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

Benzinga · 03/13/2025 10:38
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and maintains $1 price target.